**Monday 24 August 2026** ..... **1**
FACT Training ..... 1
**Tuesday 25 August 2026** ..... **1**
FACT Training / SIG Workshops + Dinners ..... 1
**Wednesday 26 August 2026** ..... **3**
ANZTCT ASM 2026 - Day 1 ..... 3
**Thursday 27 August 2026** ..... **6**
ANZTCT ASM 2026 - Day 2 ..... 6
**Friday 28 August 2026** ..... **9**
ANZTCT ASM 2026 - Day 3 ..... 9
**Friday 28 August 2026** ..... **11**
ANZTCT Satellite Symposium ..... 11

## Monday 24 August 2026

FACT Training

| | |
|---|---|
| 8:00am - 5:00pm | **FACT Quality Bootcamp (by invitation/EOI - please contact info@anztct.org.au)**<br>*Venue: Pullman East Melbourne* |

## Tuesday 25 August 2026

FACT Training / SIG Workshops + Dinners

| | |
|---|---|
| 8:00am - 4:00pm | **FACT Accreditation Workshop (by invitation/EOI - please contact info@anztct.org.au)**<br>*Venue: Pullman East Melbourne* |
| 8:30am - 5:30pm<br>6:30pm – 9:00pm | **ANZTCT Data Manager Workshop – *supported by Link Healthcare***<br>*Venue: Pullman East Melbourne*<br>**Data Manager Dinner - *supported by Link Healthcare***<br>*Venue: The Tippler & Co*<br>**RSVP to attend** |
| 9:30am – 4:30pm<br><br>6:30pm – 9:00pm | **ANZTCT Nursing and Pharmacy Education Day – *supported by Therakos and Abbvie***<br>*Venue: Pullman East Melbourne*<br>**Nurses and Pharmacists Dinner – *supported by JAZZ***<br>*Venue: East Melbourne Room, Roccella Restaurant*<br>**RSVP to attend** |
| 8:45am - 5:00pm<br>6:00pm - 9:00pm | **Scientist Workshop** – *Venue: Pullman East Melbourne*<br>**ANZTCT Quality Manager + Scientists Spotlight Dinner**<br>*Venue: La Cantina Room, Roccella Restaurant*<br>**RSVP to attend** |

*Kindly note this program is subject to change.*

YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion

2L R/R LBCL

## WITH YESCARTA YOU MAY

# UNLEASH THEIR CURE WITHIN[1-4*†]

**Choose YESCARTA for the best chance at a cure vs standard therapy for LBCL patients who are refractory to or relapse within 12 months of completing first-line treatment[1-4*†]**

*Cure in LBCL can be defined as when the therapy has been stopped and the survival curve plateaus; 3-year OS data; and/or at least 2-year EFS data.[3-6]

†**60% reduction in risk of EFS events at 2 years** vs SOCT (HR=0.40; 95% CI: 0.31-0.51; p<0.001) & **55% of patients alive at 4 years** vs 46% with SOCT (HR=0.73; 95% CI: 0.54-0.98; p=0.03).[2,7]

In ZUMA-7 axi-cel arm (n=170), **92% of patients reported CRS (6% Grade ≥3) and 60% reported neurologic toxicities (21% Grade ≥3)**. No changes in cumulative treatment-related serious adverse events occurred with 47.2 months median follow-up.[2,7]

Event-free survival was defined as the time from randomisation to the earliest date of disease progression per the Lugano classification (Cheson 2014), the commencement of new lymphoma therapy, death from any cause, or a best response of stable disease up to and including the day 150 assessment; and was assessed according to blinded central review. OS was a secondary endpoint, OS are descriptive. Kaplan-Meier estimated OS, stratified two-sided log-rank test.[2]

Please see Product Information and Risk Management Plan for full details on managing adverse events.

YESCARTA is funded for the treatment of patients with CD19-positive LBCL who are relapsed or refractory no more than 12 months after first-line chemoimmunotherapy; and for the treatment of patients with relapsed or refractory DLBCL, PMBCL, TFL and HGBCL, following AUTO-SCT or two prior systemic therapies, under the National Health Reforms Act arrangements. Full Product Information available by scanning the QR code and should be reviewed before using YESCARTA. Full Product Information is also available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-PI-01535-1.

Abbreviations: 2L: second-line; CI: confidence interval; CRS: cytokine release syndrome; EFS: event-free survival; HR: hazard ratio; OS: overall survival; R/R LBCL: relapsed-refractory large B cell lymphoma; SOCT: standard of care therapy. References: 1. YESCARTA Product Information. 2. Westin J *et al. N Engl J Med* 2023;389:148-157 (inc. Suppl Appendix). 3. Ravi P *et al. Blood Cancer J* 2018;8:26. 4. Patel A *et al. Blood* 2023;142:6899. 5. Howlader N *et al. Cancer* 2017;123:3326-3334. 6. Maurer M *et al. J Clin Oncol* 2014;32:1066-1073. 7. Locke F *et al. N Engl J Med* 2022;386:640-654 (inc. Suppl Appendix). YESCARTA, the Yescarta Logo, KITE PHARMA, and the Kite Logo are trademarks of Kite Pharma Inc. GILEAD and the Gilead Logo are trademarks of Gilead Sciences, Inc. or one of its related companies. ©2026 Gilead Sciences Pty Ltd, ABN 71 072 611 708, Level 28, 385 Bourke Street, Melbourne VIC 3000. Call Toll Free: 1800 806 112. AU-YES-0407 EMVYES0165 Date of preparation: July 2026.

Scan here to access the YESCARTA Product Information

GILEAD | Kite

**WARNINGS:**

**CYTOKINE RELEASE SYNDROME** Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.

**IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME** Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which may be fatal or life-threatening, has occurred following treatment with YESCARTA, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with YESCARTA. Provide supportive care and/or corticosteroids as needed.

| Wednesday 26 August 2026<br>ANZTCT ASM 2026 - Day 1 | |
|---|---|
| From 7:30am | **Registration** – **Betty Cuthbert Lounge - Level 2, Olympic Stand (Gate 3), MCG** |
| 8:00am - 8:30am | **Opening of ANZTCT ASM 2026**<br>*Chairs: Prof Nada Hamad and A/Prof Mary Ann Anderson*<br>• Welcome to Country: Wurundjeri Elder, Uncle Perry Wandin<br>• Maori Address: Dr Matthew Wheeler<br>• President's Address: Prof Nada Hamad |
| ***Precision Transplantation: From Biology to Bedside***<br>***Chairs: Dr Shanti Ramachandran and Dr Travis Perera*** | |
| 8.30am - 9.10am | **Keynote Presentation: What Adult Transplanters Can Learn from Paediatric Transplanters and Vice Versa**<br>Speaker: Prof Catherine Bollard<br>*T cell therapies after Bone Marrow Transplantation (BMT) have progressed from donor lymphocyte infusion (DLI) to antigen specific T cell therapies (including targeting viruses and tumour associated antigens) to CAR-T. The first EBV-specific T cell therapy study was reported in paediatric patients after BMT. The first FDA approval of a CAR-T cell therapy was for paediatric patients with leukaemia who had released after BMT. Since then, there have been substantial advances in T cell therapeutics for BMT patients. This keynote highlights how paediatric innovation helped moved some of these therapies into the mainstream and will discuss strategies for broadening applicability and access for both adult and paediatric patients after BMT.* |
| 9:10am - 9:30am | **Presentation: Precision Dosing in Transplant: Right Drug, Right Patient, Right Time**<br>Speaker: Rachael Lawson<br>*Therapeutic drug monitoring and pharmacogenomics are converging to enable truly individualised dosing strategies in transplant medicine. This session explores how precision dosing can reduce toxicity, improve efficacy, and optimise outcomes across transplant populations.* |
| 9:30am - 9:50am | **Presentation: The Hidden Half of Transplant: Supporting carers for better outcomes**<br>Speakers: Georgia Janas and Amanda Mellow<br>*A quality improvement initiative exploring practical approaches to screening and supporting carers to enhance transplant outcomes.* |
| 9:50am -10:30am | **Debate: CAR T is the 'B-ALL' and end-all - consolidation is unnecessary**<br>Speakers: A/Prof Shaun Fleming (Negative) Vs Dr Madeleine Powys (Affirmative)<br>*With CAR T driving deeper, longer-lasting responses, does consolidation still have a role - or is it redundant? This fast-paced debate tackles relapse risk, toxicity, and the latest evidence head-on.* |
| 10:30am - 11:00am | **Morning Tea** - *Sponsored by Arovella* |
| 11:00am - 12:00pm | **Oral Abstracts: Presidential - Chairs: A/Prof Andrea Henden and Leonie Wilcox**<br>Dr Katherine Cummins: *Trial in progress - Early clinical data From "PLATYPS", a first-in-human clinical trial of an Australian-developed and manufactured CD19-targeting CAR-T cell product (PMCC-COE19)*<br>Prof Nada Hamad: *Allogeneic stem cell transplantation for sickle cell disease in Australia and New Zealand: outcomes, unmet demand and the arrival of gene therapy*<br>Elias Biris: *Weight-adjusted ATG dosing improves relapse-free survival in obese allo-HSCT recipients* |

*Kindly note this program is subject to change.*

| Wednesday 26 August 2026<br>ANZTCT ASM 2026 - Day 1 | | |
|---|---|---|
| | Dr Miles Horton: *Multiplex prime editing enables safe, drug-controllable and immunosuppression-resistant T-cell therapies in vivo* | |
| 12:00pm - 12:20pm | **ANZTCT Award Presentations - presented by Prof Nada Hamad and Dr Duncan Purtill**<br>*A special ASM highlight, the inaugural ANZTCT Awards celebrate the achievements, dedication and leadership of members who have helped shape and advance transplantation and cellular therapies across Australia and New Zealand.* | |
| 12:20pm - 1:30pm | **Delegate Lunch** | **ANZ Donor SIG Meeting (12:30pm - 1:30pm, Jim Stynes A)** |
| | | **Lunch 'n' Learn: Myeloma CAR T in the real world, with Prof Hermann Einsele (12:40pm - 1:20pm, Olympic Room)**<br>*Sponsored by J&J*<br>*Chair: Dr Sueh-Li Lim and Ty Simpson* |
| ***TCT and Novel Agents in Lymphoma: Integrating Science, Sequencing & Patient Experience – supported by AbbVie***<br>***Chair: Dr Sam Fiorenza and A/Prof John Coutsouvelis*** | | |
| 1:30pm - 3:30pm | **Patient-led story**<br>Speaker: Chantelle Asciak<br>*A first-hand account of the bispecific therapy journey, setting the scene for the session.*<br><br>**Keynote Presentation: Sequencing Bispecifics with CAR T**<br>Speaker: Dr Julie Vose<br>*Expert clinical perspective on sequencing bispecific therapies with CAR T-cell treatment in lymphoma - looking to the future, where will bispecifics sit?*<br><br>**Presentation: Combining Chemotherapy and Bispecifics**<br>Speaker: Prof Mark Hertzberg (supported by Roche)<br>*Discussing emerging evidence and practical considerations in combining chemotherapy with bispecific antibodies.*<br><br>**Presentation: The critical role of pharmacists in outpatient care**<br>Speaker: Dr Karim Ibrahim<br>*The role of Pharmacists in supporting the delivery of novel therapies in haematology and oncology outpatient care.*<br><br>**Presentation: Nursing Perspective: Quality of Life**<br>Speaker: Emily Knights, Lymphoma Australia<br>*Patient experience and QoL considerations during bispecific therapy.*<br><br>**Panel Discussion + Audience Q&A**<br>Panellists: Dr Julie Vose, Prof Mark Hertzberg, Dr Karim Ibrahim, Emily Knights, Chantelle Asciak - Moderated by Dr Sam Fiorenza<br>*Bringing together clinical, pharmacy, nursing, and patient perspectives on the future of bispecifics in lymphoma care.* | |
| 3:30pm - 4:00pm | **Afternoon Tea** - *Sponsored by Ascentage Pharma* | |

*Kindly note this program is subject to change.*

| Wednesday 26 August 2026<br>ANZTCT ASM 2026 - Day 1 | |
|---|---|
| 4:00pm - 5:00pm | **Debates**<br>**Chair: Prof David Yeung**<br>**Topic: PTCy reigns supreme: everyone should get PTCy**<br>Dr Clinton Lewis (Negative) Vs A/Prof Siok Tey (Affirmative)<br>*A spirited debate on whether PTCy should be universal standard practice or reserved for selected settings.*<br>---<br>**Topic: Ruxolitinib vs ECP in GVHD management**<br>Prof David Ritchie (Rux) Vs Prof Nada Hamad (ECP)<br>*A head-to-head comparison of two very different approaches to immune modulation in GVHD — science, experience, and a bit of friendly rivalry.* |
| 5:00pm – 6:00pm | **Poster Session and Welcome Drinks - Betty Cuthbert Lounge** |

*Kindly note this program is subject to change.*

| Thursday 27 August 2026<br>ANZTCT ASM 2026 - Day 2 | |
|---|---|
| 7:30am - 8:30am | **Networking Breakfast - Betty Cuthbert Lounge, MCG**<br>*Please join us for a light breakfast from **7:30am**! It's a great opportunity to catch up with our sponsors, take a look at any posters you may have missed the night before, and soak up the MCG atmosphere before the day's program gets underway.*<br>***Everyone is welcome!*** |
| ***Everyone gets a Donor!***<br>***Chair: A/Prof Carmel O'Brien and A/Prof Andrea Henden*** | |
| 8:30am – 9:40am | **Donor-led story**<br>*A conversation with Mitchell Eldridge bringing his personal perspective on stem cell donation into focus; convened by Kate Levy*<br><br>**Keynote Presentation: Allogeneic Donor Selection - Contemporary Guidelines from NMDP/CIBMTR**<br>Speaker: Stephen Spellman - *Supported by Stem Cell Donors Australia*<br>*A plenary on how registry science is reshaping donor choice and optimising outcomes in contemporary transplant practice.*<br><br>**Presentation: Stem Cell Donors executive update**<br>Speaker: Garth Healey<br>*A brief update on registry priorities, strategy, and developments supporting donor access, welfare and matching.* |
| ***Optimising TCT Outcomes: From Practice Statements to Global Perspectives***<br>***Chairs: Prof Joy Ho and Nicole Loft*** | |
| 9:40am - 10:50am | **Presentation: ANZTCT Practice Statement - Optimising Pre-TCT AML Care**<br>Speaker: A/Prof Ashish Bajel<br><br>**Presentation: ANZTCT Practice Statement - Optimising CMV Outcomes in TCT**<br>Speaker: A/Prof Andrea Henden<br><br>**Presentation: ANZTCT Practice Statement - Optimising VOD Outcomes following TCT**<br>Speaker: A/Prof Shaun Fleming<br><br>**Keynote Presentation: Managing CAR T Toxicities in Myeloma**<br>Speaker: Prof Hermann Einsele<br>*Practical strategies for managing CAR T toxicities, including CRS and ICANS, with a focus on optimising safety and TCT outcomes.* |
| 10:50am - 11:20am | **Morning Tea** - *Sponsored by Arovella*<br>*Allied Health SIG Meeting (11:00am - 12:00pm, Jim Stynes A)* |

*Kindly note this program is subject to change.*

| Thursday 27 August 2026<br>ANZTCT ASM 2026 - Day 2 | | |
|---|---|---|
| ***CLL in Focus: Navigating complexities and future directions – supported by Eli Lilly***<br>***Chairs: A/Prof Mary Ann Anderson and Ashley Whitechurch*** | | |
| 11:20am<br>12:30pm | **Presentation: CLL Treatment Sequencing: Biomarkers, Resistance, and Strategy**<br>Speaker: Dr Masa Lasica<br><br>**Presentation: Allograft and CAR T in highly refractory CLL (including Richter's)**<br>Speaker: Prof Constantine Tam<br><br>**Presentation: Emerging novel agents in CLL**<br>Speaker: Dr Sasanka Handunnetti<br><br>**Panel discussion**<br>*A collaborative discussion with all speakers bringing together key themes, clinical dilemmas, and future directions in CLL care; moderated by A/Prof Mary Ann Anderson* | |
| 12:30pm - 2:00pm | **Delegate Lunch** | **ANZTCT AGM (12:40pm - 1:10pm, Jim Stynes A) - *RSVP here***<br><br>**Lunch 'n' Learn: RSV in haematology patients: disease burden and prevention with Dr Tina Marinelli (1:15pm - 1:55pm, Olympic Room)**<br>*Sponsored by Pfizer*<br>*Chair: A/Prof Andrea Henden* |
| ***The Future of Transplant Science and Care***<br>***Chairs: Prof Nada Hamad and Yvonne Panek-Hudson*** | | |
| 2:00pm - 2:40pm | **Keynote Presentation: TCT science and capability building - followed by Q+A**<br>Speaker: A/Prof Folashade Otegbeye<br>Exploring advances in TCT science and strategies for building clinical and system capability to support evolving therapies. | |
| 2:40pm - 3:20pm | **Keynote Presentation: Beyond Protocol: Personalised preparation and parallel planning for transplant and cell therapy - followed by Q+A** *(supported by Therakos)*<br>Speaker: Sara Main | |
| 3:20pm – 3:30pm | **Arrow Foundation update**<br>Speaker: Richelle Koller | |
| 3:30pm - 4:00pm | **Afternoon Tea** - *Sponsored by Ascentage Pharma*<br>*Nursing Committee AGM (Jim Stynes A)* | |

*Kindly note this program is subject to change.*

| Thursday 27 August 2026<br>ANZTCT ASM 2026 - Day 2 | |
|---|---|
| 4:00pm - 5:00pm | **Oral Abstracts - Chairs: Yvonne Panek-Hudson and Phil Selby**<br>Lotte Fog: *Total Body Irradiation in Australia and New Zealand: A 2024 Practice Survey on Changing Patterns of Care*<br>Erica Patterson: *Early Identification Matters: Feasibility and Early Outcomes of a Nutrition and Exercise Program in Allogeneic Versus Autologous Stem Cell Transplant Recipients*<br>Cassie Abbott: *Building a Skilled and Confident CAR-T Nursing Workforce: Assessing the Impact of Nurse-led CAR-T Education*<br>Dr Salvatore (Sam) Fiorenza: *Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (ANTLER phase 1 clinical trial)* |
| 5:00pm - 6:30pm | Delegate break |
| 6:30pm - 9:30pm | **ASM Dinner - Paint the Town RED with Arrow – The George on Collins** |

*Kindly note this program is subject to change.*

| Friday 28 August 2026<br>ANZTCT ASM 2026 - Day 3 | |
|---|---|
| **The Members' Dining Room, Level 2, The Members' Reserve (Gate 2), MCG** | |
| ***7:30am - 8:30am*** | ***Career Planning Breakfast – The Terrace Cafe, Level 2, The Members' Reserve (Gate 2), MCG - RSVP here*** |
| ***Optimising Equity - Levelling the playing field***<br>***Chairs: Dr Min-Hi Han and Dr Leah Peters*** | |
| 8:30am - 9:30am | **Session: Innovations in Equity: Opening Access for Older and Underserved Patients in TCT**<br><br>**Presentation: Equity in Practice - Insights from a Fulbright scholar**<br>Speaker: Prof Nada Hamad<br>*Focusing on advancing equity in TCT through innovative solutions.*<br><br>**Presentation: Assessment of Sarcopenia and Frailty in TCT Selection**<br>Speaker: A/Prof Nicole Kiss<br>*How sarcopenia and frailty assessment can better define risk and support more equitable access to TCT, enabling safer, individualised treatment decisions for older patients.*<br><br>**Presentation: Who Gets Left Behind? Employment Inequity and Financial Toxicity After Allogeneic Stem Cell Transplant**<br>Speaker: Dr Genevieve Douglas<br>*Exploring the long-term impact of allogeneic stem cell transplantation on employment, income, financial well-being, and the inequities experienced by survivors returning to everyday life.*<br><br>**Presentation: Māori Perspectives on Equity in TCT**<br>Speaker: Dr Myra Ruka<br>*A Māori worldview on equity in TCT, emphasising whānau-centred care, culturally grounded practice, and partnership in improving access and outcomes.* |
| 9:30am – 10:30am | **Oral Abstracts - Chairs: Celeste Hill and Daniel Kilmartin**<br>Nicole O'Leary: *Intensive care unit utilisation amongst chimeric antigen receptor T-cell recipients: a single centre experience*<br>Kate Graham: *Development of a nutrition care pathway for haematology cancer patients undergoing chimeric antigen receptor T-Cell (CAR-T) therapy*<br>Dr Karim Ibrahim: *Evaluating the impact of a dedicated outpatient pharmacy clinic on medication safety and transitions of care for patients undergoing haematopoietic stem cell transplantation*<br>Dr Marzia Rahman: *Renal Function at Stem Cell Infusion Stratifies Risk of Cyclosporine Associated Acute Kidney Injury in PTCy Based AlloHSCT* |
| 10:30am - 11:00am | **Morning Tea -** *Sponsored by Arovella* |

*Kindly note this program is subject to change.*

## Friday 28 August 2026

ANZTCT ASM 2026 - Day 3

**The Members' Dining Room, Level 2, The Members' Reserve (Gate 2), MCG**

***Equity in TCT: From Data to Policy and Access***
***Chairs: Prof Nada Hamad and A/Prof Edward Abadir***

| | |
|---|---|
| 11:00am - 12:00pm | **Session: Driving Improvement Through Registry Data**<br>*The ANZTCT Registry supports quality improvement and equitable access to transplantation and cellular therapies through benchmarking, government reporting, research, and the generation of real-world evidence to inform clinical practice and health service planning. This session highlights Registry developments, reporting activities, data enhancement opportunities, and new technology supporting data collection and use.*<br><br>**Registry Update: The evolving ANZTCT Registry**<br>Speaker: Leonie Wilcox - Registry Executive Director<br><br>**ANZTCT Benchmarking and CQR government reporting**<br>Speaker: Dr Ed Abadir - Deputy Chair, Registry Committee<br><br>**ANZTCT Data Enhancement Opportunity: Integrating higher quality HLA data (IHWG)**<br>Speaker: Dr Dianne De Santis<br><br>**Demonstration of the new ANZTCT platform**<br>Speaker: Dr Navid Toosi Saidy - CEO & Co-founder, Propel Health AI and Steven Tran - Registry Tech Lead |
| 12:00pm - 1:00pm | **Opening: The importance of engaging government and how**<br>Speaker: Senator Dr Michelle Ananda-Rajah<br><br>**Panel Discussion: Planning for the future - the promise of gene therapy**<br>*A revolutionary development in Sickle Cell Disease in Australia is the role out of heel prick screening. This will identify patients early for potential curative therapies including allogeneic stem cell transplantation. The population is small but vulnerable. The promise of gene therapy will require concerted efforts to plan services and develop models of care to ensure cultural safety and equitable access.*<br><br>Panellists: Senator Dr Michelle Ananda-Rajah, Agnes Nsofwa, Dr Kylie Mason, Claire Dowsing, Prof Robyn Langham |
| 1:00pm - 1:10pm | **ANZTCT ASM 2026 Close** |
| 1:10pm - 2:00pm | **Delegate Lunch**<br>*Followed by Plasma Cell Dyscrasia Satellite Symposium at the Pullman East Melbourne, commencing at 2:00pm (all ASM delegates welcome)* |

*Kindly note this program is subject to change.*

| Friday 28 August 2026<br>ANZTCT Satellite Symposium | |
|---|---|
| **Jolimont Room, Pullman East Melbourne – 192 Wellington Parade, East Melbourne, VIC 3002** | |
| 2:00pm - 5:30pm | **PLASMA CELL DYSCRASIA SATELLITE SYMPOSIUM – SPONSORED BY PFIZER**<br>*Opened by Dr Sam Fiorenza; Chair: A/Prof Amit Khot* |
| 2:10pm – 3:40pm | **Session 1: Expanding the Role of Bispecifics Across Patient Populations**<br><br>**Bispecifics in High-Risk Disease**<br>Speaker: Prof Andrew Spencer<br>**IVIG in the Bispecific Era**<br>Speaker: Prof Erica Wood<br>**Bispecifics in Amyloidosis**<br>Speaker: Dr Olga Motorna<br>**Bispecifics in the Elderly**<br>Speaker: Dr Adam Bryant<br>**Panel Discussion & Audience Q&A (30 min)**<br>*All session 1 speakers, moderated by A/Prof Amit Khot* |
| 3:40pm – 4:00pm | **Afternoon Tea break** - *Sponsored by Ascentage Pharma* |
| 4:00pm – 5:30pm | **Session 2: Translating Bispecifics and Cellular Therapies into Practice**<br><br>**Keynote Presentation: What will the Myeloma Treatment Algorithm be in 2027?**<br>Speaker: Prof Evangelos Terpos<br>**Feasibility of Outpatient Administration**<br>Speaker: Daniela Klarica<br>**Debate: CAR-T before the Horse (bsAb)?**<br>Prof Joy Ho (Negative) Vs A/Prof Cindy Lee (Affirmative)<br>**Closing Remarks & Key Takeaways**<br>*Synthesis of key themes and future directions* |
| 6:30pm - 9:00pm | **Symposium dinner (by invitation - faculty and speakers) - supported by Pfizer** |

*Kindly note this program is subject to change.*